The performance of IVD leading enterprises has different performance, and the new business layout is welcoming the speed

The 21st Century Business Herald reporter Tang Weiko's intern Yang Siqi Guangzhou reported that recently, the IVD industry leader listed enterprises densely released the first half of the performance preview.

On the evening of July 14, Jiu'an Medical (002432) issued a semi -annual performance forecast. It is expected that during the reporting period, the net profit of the mother is expected to be 15.1 billion yuan to 15.5 billion yuan, an increase of 27466.36%over the same period last year to 28196.60%. The net profit of Mingde Biological (002932) is expected to be 2.4 billion to 2.75 billion yuan, an increase of 314.11%to 374.50%over the same period last year.

On the other hand, the net profit attributable to shareholders of listed companies in the first half of 2022 is 35 million-50 million, a year-on-year decrease of 89.56%-92.69%of the shareholders of listed companies. In addition, Kahua Biological will be reviewed on April 28, 2022 and decided to not be included in the company's merger statement from October 1, 2021. Since Tianlong Company has not included the merger statement, the Shanghai epidemic sealing control has the impact on the operation of the business and the incidence of partial stop work losses, the company's current R & D investment growth, and the impact of the reduction of income from overseas business. A significant decline in the same period last year. In addition, companies such as Huada Gene, Lepu Medical and Mike Biological have declined year -on -year.

Circuit differentiation

In the first half of this year, the domestic epidemic was repeated and distributed. In order to further optimize the new coronal virus testing strategy, according to the needs of the epidemic. On March 12, the State Council ’s joint prevention and control mechanism comprehensive group decided to promote the monitoring model of“ antigen screening and nucleic acid diagnosis ”, and increase the antigen detection as a supplement based on nucleic acid detection.

As of now, the State Drug Administration has approved 31 new coronary virus antigen test agents. These include new coronary virus (2019-NCOV) antigen detection kites produced by Normana, Mingde Biological, Yahuilong, Wantai Bio and other companies.

Judging from the preview of the first half of the first half of the company's disclosed, most of the performance has increased compared with the same period last year. In the report, each enterprise also mentioned the impact of the new crown business on its revenue.

According to the semi -annual report disclosed by Yahuilong, the company achieved operating income of 2.337 billion yuan, an increase of 326.46%year -on -year. The new crown business achieved revenue of 1.819 billion yuan, accounting for about 77.84%. According to the report, due to the changes in the product structure of the new crown business, the main sales are new -type coronary virus antigen test kits (collagen gold method) with average gross profit margin, which has increased the gross profit margin of the new crown business by 10.25 percentage points to 55.11%.

In the first half of the year, Jiu'an Medical, which received much attention, said that its performance report said that due to the significant increase in sales revenue during the reporting period, the company's performance during the reporting period also increased significantly compared with the same period last year. During the reporting period, affected by the development of the U.S. epidemic, the demand for local new crown antigen testing kits increased significantly. The company's IHEALTH kit product was authorized by the US FDA EUA, and used the company's independent brand "IHEALTH" to sell TO C -end sales through the US subsidiary website and the Amazon American e -commerce platform, and also undertake government orders and commercial orders. And this kit product has formed a complete value chain from R & D, design, manufacturing to independent brand sales. While enjoying R & D and manufacturing profits, it also enjoys market access and brand premiums.

The repetition of the new crown epidemic has improved the overall performance of the IVD industry to a certain extent. At the same time, competition followed. The business income related to the company's new crown is decreased compared with the same period of 2021. Except for the China University of Gene, companies such as Kehua Biological and Lepu Medical have begun to have a sign of decline in performance.

Cobo Bio is expected to return to the mother of 35 million to 50 million in the first half of 2022, a decrease of more than 90%year -on -year. In the semi -annual performance trailer released by Lepop Medical, it can be known that the company's net profit returned by the company in the first half of the year is expected to be 1.208 billion yuan to 1.38 billion yuan, a year -on -year decrease of 20%to 30%. The company achieved a total operating income of 5.33 billion yuan, a year -on -year decrease of 18%. Among them, the revenue of new crown testing related business decreased by 80%year -on -year, and the total revenue of total revenue decreased from 37%last year to 9%.

Enterprises hurry up with new layout

It is not difficult to see that the first half of the performance trailer and the financial report in the first quarter, the revenue of some companies in the second quarter was slower compared to the first quarter. Even Jiu'an Medical, which has soared, is difficult to escape. The first quarter of net profit was 14.312 billion yuan. As a result, the net profit of Jiu'an Medical in the second quarter of this year was only about 788 million yuan to 1.188 billion yuan.

Novzan's revenue and profits in the second quarter also decreased compared with the first quarter. It is estimated that the company's revenue in the first half of 2022 was 16.65 billion yuan, a year -on -year increase of 93.8%to 99.9%, and the estimated revenue in the second quarter was 6.25 to 675 million yuan, a year -on -year increase of 120.1%to 137.7%; 6 to 630 million yuan, a year -on -year increase of 53.1%to 60.8%, corresponding to the net profit of the mother in the second quarter of 1.69 to 199 million yuan, an increase of 207.3%to 261.8%year -on -year.

The first quarterly report released by Mingde Biological shows that the company deducted non -net profit of 1.385 billion yuan in the first quarter, an increase of 307.04%year -on -year. Last year, the non -net profit was 1.403 billion yuan, and the profit in the first quarter could be compared with the full -year profit of last year. In response to some investors asking the company's income in the second quarter, Mingde Bio publicly responded that the main reason was that the price of new coronary virus nucleic acid detection and antigen detection was reduced. It is reported that when the antigen detection reagent was just listed in the pharmacy in early March this year, the single retail price generally reached 19 yuan or even 20 yuan. At present, the single -portal retail price of terminals such as pharmacies is more than 10 yuan.

Concentrated procurement has further squeezed the profit of corporate profits. A research report on Mike Biological states that the sales volume of the new crown nucleic acid reagent of the Mike biomolecular platform increased by 98.2%in the first half of the year. The gross profit margin decreased by 19.02%.

Nowadays, the supply of new crown testing products and the fierce competition in the industry, coupled with the normalization of the epidemic situation, the corporate profit space is inevitable. Although some research institutions are optimistic about IVD companies relying on new crown business revenue, they are concerned about their unsustainable risks.

Faced with this uncertain factors, while expanding overseas markets, domestic IVD companies have stepped up new business layouts.

On July 18, Daannin accepted a group of institutions for investigations. Among them, for the future layout, Daan gene replied that the company will fully enter the entire field of IVD in the future, focusing on the clinical and public clinical and public of the diagnostic technology and products. Sanitary, inspection and quarantine, life and health related fields, etc., continue to make bigger and stronger PCR and molecular diagnostic technology, products and market fields, and actively develop full diagnostic technology platforms, products and market areas such as immunity, biochemistry, and analysis instruments.

Not only that, but also IVD companies are preparing to enter a new field.

On June 20, An Xu Bio said during the investigation of the agency: "The company is paying attention to the small molecular drugs and antibody drugs of the new crown. If there is a good opportunity, we will try to participate. Except, the company recently passed 500 million funds of 500 million funds. Yuan and the central enterprise China Chuanjin Holdings cooperated with 1 billion yuan of industrial funds, mainly investing in enterprises or projects in the fields of pharmaceutical, large health, biomedicine and other fields in the entrepreneurial period, growth period. "

Researchers in a certain level of institutions in Shenzhen told the 21st Century Business Herald reporter: "In the future, the industry's competition is accelerating, and some companies will turn to small molecular drug research and trying phenomena. The transformation of these companies in the future still needs to be observed. "

Zhejiang Shang Securities specifically mentioned the biomedical sector in the comments of Nuo Weizan 2022 in the first half of the annual performance trailer. After the 2021 cultivation period, Normatan has formed a relatively stable customer acquisition channel and service model. The construction of the first half of the year is currently in the customer verification stage. It is expected that the performance contribution of 2022-2024 is greater. GPM is a set of mandatory standards for pharmaceuticals, food and other industries. The GMP workshop meets the requirements of the GMP quality and safety management system.

- END -